Meeting
2016 ASCO Annual Meeting
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.
Authors
Tanguy Y. Seiwert
University of Chicago, Chicago, IL
Tanguy Y. Seiwert , Jared Weiss , Shrujal S. Baxi , Myung-Ju Ahn , Jerome Fayette , Maura L. Gillison , Jean-Pascal H. Machiels , Shunji Takahashi , Giovanni Melillo , April Franks , Ugochi Emeribe , David Raben , Michael McDevitt , Amanda Psyrri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02551159
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS6101)
DOI
10.1200/JCO.2016.34.15_suppl.TPS6101
Abstract #
TPS6101
Poster Bd #
423a
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt D. Galsky
Poster
2016 ASCO Annual Meeting
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
First Author: Thomas Powles
First Author: Matt D. Galsky
Poster
2017 ASCO Annual Meeting
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
First Author: Gerard Zalcman